The Role of Runx3 in Host Response to Influenza Virus Infection
Runx3 在宿主对流感病毒感染反应中的作用
基本信息
- 批准号:9751196
- 负责人:
- 金额:$ 18.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-01 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAddressAffectAlveolarAnimalsApoptosisBacterial InfectionsBirthBody Weight decreasedCell DeathCellsCessation of lifeConstitutionalCritical IllnessDataDiseaseDisease ProgressionDouble-Stranded RNAEmbryonic DevelopmentEpidemicEpithelialEpithelial CellsFutureHumanImmune responseIn VitroInfectionInflammationInflammatoryInflammatory ResponseInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A virusInnate Immune ResponseInterferonsInterleukin-1Interleukin-12Interleukin-18Interleukin-6Knock-outKnockout MiceLeadLeukocytesLungLung InflammationMediator of activation proteinMolecularMorbidity - disease rateMusMutationPathogenesisPathogenicityPatientsPermeabilityPlayPoly I-CProductionPulmonary function testsRANTESRUNX3 geneReportingRespiratory FailureRoleSeveritiesSystemT-LymphocyteTLR3 geneTNF geneTNFSF10 geneTestingTimeToll-like receptorsUnited StatesVaccinesViralViral Load resultViral PneumoniaVirulentVirusVirus DiseasesVirus ReplicationWorld HealthX-Ray Computed Tomographyacquired immunityage groupairway epitheliumanalogcombatcytokinedesignhealth economicsin vivoinfluenza outbreakinfluenzaviruslung injurymortalitymouse modelnovelnovel strategiespandemic diseasepostnatalpulmonary functionrecruitrespiratoryresponseseasonal influenzatargeted treatmenttranscription factorviral RNA
项目摘要
Influenza A virus (IAV) targets lung epithelial cells and exploits the host cell machinery to replicate, causing
respiratory illness in annual epidemics and pandemics of variable severity. Influenza affects all age groups,
results in considerable morbidity and mortality, and exacts a formidable toll on world health and economics.
Seasonal influenza causes 250,000 to 500,000 deaths worldwide and about 36,000 deaths in United States
annually. Current therapies target the virus and are therefore limited by the capacity of influenza to rapidly
evolve and are frequently ineffective in critically ill patients. One critical aspect of IAV-induced pathogenesis is
lung epithelial cell death and inflammation, which compromises pulmonary function and contributes to disease
morbidity and mortality. Hence it has been proposed that identification of and targeting key inducible host cell
factors that regulate IAV-induced lung injury, inflammation and viral replication may provide a potential solution
to combat future influenza outbreaks. We recently reported that transcription factor Runx3, but not Runx1 and
Runx2, was induced by IAV infection, viral RNA, a synthetic double-stranded RNA (dsRNA) analog
polyinosinicpolycytidylic acid (poly(I:C)) and interferon- (IFN) in normal human airway epithelial cells and
demonstrated that Runx3 played a crucial role in the cell death such as apoptosis induced by IAV infection and
dsRNA. Moreover, our new preliminary data indicate that Runx3 can be induced in IAV-infected mouse airway
and alveolar epithelial cells in vivo and is an important mediator of the expression of dsRNA receptor Toll-like
receptor 3 (TLR3) that contributes to a detrimental host inflammatory response to IAV infection. As IAV initially
infects the airway epithelium and induces robust innate immune response, our novel findings prompt us to
develop mice with airway epithelium specific knockout (KO) of Runx3 to test the hypothesis that the inducible
transcription factor Runx3 may be a novel and crucial regulator of airway epithelial cell pathogenic responses
to IAV infection and the disease progression of influenza in vivo. Two specific aims will be tested in this
proposal. Aim-1 will generate airway epithelium specific Runx3 conditional KO mice and determine the effect of
Runx3 conditional KO on lAV-induced disease progression; Aim-2 will determine the role and mechanism of
Runx3 in IAV-induced lung injury and inflammation. This R21 proposal will reveal the airway epithelium specific
role of Runx3 in host responses to IAV infection and the disease progression of influenza. This proposal will
also enable us to assess if controlling the initial pathogenic response in the airway epithelial compartment
could limit the overall lung injury and inflammation, which may lead to recognition that modulation of Runx3
offers a novel strategy to control host pathogenic response to the infection of virulent IAV.
甲型流感病毒(IAV)以肺上皮细胞为目标,利用宿主细胞机制进行复制,导致
年度流行病和不同严重程度的大流行中的呼吸系统疾病。流感影响所有年龄段,
导致相当大的发病率和死亡率,并对世界卫生和经济造成巨大损失。
季节性流感导致全球25万至50万人死亡,美国约3.6万人死亡
每年一次。目前的治疗是针对病毒的,因此受到流感快速传播能力的限制。
在危重病人身上往往无效。IAV诱导致病的一个关键方面是
肺上皮细胞死亡和炎症,损害肺功能并导致疾病
发病率和死亡率。因此,已经提出了识别和靶向关键可诱导宿主细胞
调节IAV引起的肺损伤、炎症和病毒复制的因素可能提供一个潜在的解决方案
以对抗未来的流感暴发。我们最近报道了转录因子Runx3,但不是RUNX1和
Runx2,是由IAV感染诱导的病毒RNA,是一种合成的双链RNA(DsRNA)类似物
多聚肌胞苷多胞酸(Poly(I:C))和干扰素-(干扰素-)在正常呼吸道上皮细胞和
证实Runx3在IAV感染诱导的细胞死亡等细胞死亡中起重要作用
DsRNA。此外,我们的新的初步数据表明,在IAV感染的小鼠呼吸道中可以诱导Runx3
和肺泡上皮细胞,是dsRNA受体Toll样蛋白表达的重要介质
受体3(TLR3),有助于对IAV感染产生有害的宿主炎症反应。最初作为IAV
感染呼吸道上皮并诱导强大的先天免疫反应,我们的新发现促使我们
用呼吸道上皮特异性Runx3基因敲除(KO)的小鼠来验证这样的假设
转录因子Runx3可能是呼吸道上皮细胞致病反应的重要调节因子
对IAV感染和体内流感的疾病进展的影响。两个具体的目标将在这方面受到考验
求婚。AIM-1将产生呼吸道上皮细胞特异性Runx3条件性KO小鼠,并确定其对
RUNX3条件KO对LAV诱导的疾病进展的影响;AIM-2将确定AIM-2的作用和机制
RUNX3在IAV诱导的肺损伤和炎症中的作用该R21方案将揭示呼吸道上皮细胞的特异性
Runx3在宿主对IAV感染的反应和流感疾病进展中的作用这项提议将
也使我们能够评估是否控制了呼吸道上皮腔内的初始致病反应
可以限制整体肺损伤和炎症,这可能导致认识到Runx3的调节
为控制宿主对强毒IAV感染的致病反应提供了一种新的策略。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HUA TANG其他文献
HUA TANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HUA TANG', 18)}}的其他基金
Protein Kinase D3 as a Novel Biomarker for Triple-negative Breast Cancer
蛋白激酶 D3 作为三阴性乳腺癌的新型生物标志物
- 批准号:
8786738 - 财政年份:2014
- 资助金额:
$ 18.35万 - 项目类别:
Protein Kinase D2 Function and Signaling in Angiogenesis
蛋白激酶 D2 在血管生成中的功能和信号转导
- 批准号:
8191770 - 财政年份:2011
- 资助金额:
$ 18.35万 - 项目类别:
Protein Kinase D2 Function and Signaling in Angiogenesis
蛋白激酶 D2 在血管生成中的功能和信号转导
- 批准号:
8298983 - 财政年份:2011
- 资助金额:
$ 18.35万 - 项目类别:
PKD Family Kinase Function and Signaling in Lung Fibroblasts
肺成纤维细胞中 PKD 家族激酶的功能和信号转导
- 批准号:
8048817 - 财政年份:2010
- 资助金额:
$ 18.35万 - 项目类别:
PKD Family Kinase Function and Signaling in Lung Fibroblasts
肺成纤维细胞中 PKD 家族激酶的功能和信号转导
- 批准号:
8204401 - 财政年份:2010
- 资助金额:
$ 18.35万 - 项目类别:
RECONSTRUCTING GENETIC ANCESTRY BLOCKS IN ADMIXED INDIVIDUALS
重建混合个体的遗传祖先区块
- 批准号:
7601006 - 财政年份:2007
- 资助金额:
$ 18.35万 - 项目类别:
Tyrosine Phosphatases and Endothelial Dysfunction
酪氨酸磷酸酶和内皮功能障碍
- 批准号:
6538128 - 财政年份:2001
- 资助金额:
$ 18.35万 - 项目类别:
Tyrosine Phosphatases and Endothelial Dysfunction
酪氨酸磷酸酶和内皮功能障碍
- 批准号:
6638847 - 财政年份:2001
- 资助金额:
$ 18.35万 - 项目类别:
Tyrosine Phosphatases and Endothelial Dysfunction
酪氨酸磷酸酶和内皮功能障碍
- 批准号:
6458188 - 财政年份:2001
- 资助金额:
$ 18.35万 - 项目类别:
Tyrosine Phosphatases and Endothelial Dysfunction
酪氨酸磷酸酶和内皮功能障碍
- 批准号:
6747854 - 财政年份:2001
- 资助金额:
$ 18.35万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 18.35万 - 项目类别:
Research Grant